Allergan TrenibotE: First Botulinum E with 8-Hour Onset, Plus 52% of GLP-1 Patients Concerned About Facial Changes
SKIN

Allergan TrenibotE: First Botulinum E with 8-Hour Onset, Plus 52% of GLP-1 Patients Concerned About Facial Changes

By Suji · · https://www.prnewswire.com/news-releases/allergan-aesthetics-releases-findings-on-the-safety-and-efficacy-of-repeat-trenibote-treatments-and-data-on-medical-weight-loss-aesthetics-patient-behaviors-at-the-2026-american-academy-of-dermatology-meeting-aad-302727609.html
KO | EN

Allergan Aesthetics presented four posters at the American Academy of Dermatology (AAD) annual meeting on March 30, 2026. The headlines come in two parts. 18-week safety data on the new botulinum neurotoxin TrenibotE, and a behavioral survey of GLP-1 users in aesthetics.

TrenibotE, a first-in-class botulinum E

All commercially available botulinum toxins are serotype A (Botox, Dysport, Xeomin, Jeuveau, etc.). TrenibotE (trenibotulinumtoxinE) is the first serotype E to enter clinical practice, differing from A in molecular structure and time profile.

Type A typically takes 2-7 days to onset and lasts 3-4 months. TrenibotE differs. It onsets in 8 hours and lasts 2-3 weeks. Fast start, short duration: the inverse time profile.

This difference partitions clinical use cases. Suited for prescribing before short-term events like weddings, interviews, photo shoots. Also reduces risk perception for first-time users unfamiliar with type A. The “try it and if it’s not right, just wait a few days” psychology lowers the entry barrier.

18 weeks, 3-cycle repeat safety

The core trial reported at AAD 2026 was an 18-week open-label evaluation. The target was glabellar lines (between the eyebrows), with up to 3 sequential treatments evaluated for safety and efficacy.

Two key findings. Safety profile remained consistent across 3 sequential treatments. No new safety concerns and no neutralizing antibody formation detected.

Long-term type A users have been reported to develop neutralizing antibodies in some cases, gradually reducing efficacy (“immunoresistance”). The absence of antibody formation in TrenibotE’s 18-week data is meaningful. That said, 18 weeks is short for evaluating antibody formation, and longer follow-up is needed.

52% of GLP-1 users, facial change concerns

Another poster reports a behavioral survey of GLP-1 users in aesthetics. An electronic questionnaire of US healthcare professionals analyzed GLP-1 patients’ behavior patterns. Key numbers.

52%: of GLP-1-treated patients express concerns about their facial appearance. More than half perceive facial changes after weight loss.

32%: of GLP-1-treated patients are first-time aesthetics patients. They form a new market entry population.

70%: of GLP-1 patients are female. 56% are aged 30-49.

82%: cite cost as the primary barrier to procedures. The second is fear of unnatural results (58%).

The industry message is direct. GLP-1 is no longer just a weight loss drug. A new aesthetic population is forming around accumulated side effects: facial volume loss, skin laxity, hair shedding. Combined with NewBeauty’s GLP-1 hair shedding clinical observations from Dr. Russak the same quarter, the GLP-1 aesthetic care category is settling in quickly.

TrenibotE matched to GLP-1 patients

The interesting alignment is between TrenibotE’s time profile and the 32% of GLP-1 patients who are first-time recipients. First-timers carry strong concern about unnaturalness (58%). Type A botulinum’s 3-4 month duration can feel like a burden to first-timers. TrenibotE’s 2-3 week duration provides reassurance: “if I make a mistake, it ends quickly.”

Combined with same-quarter aesthetic procedure trends, an aesthetic prescribing matrix for the GLP-1 era takes shape. Dermal fillers for facial volume loss, skin tightening for laxity, PRP/exosomes for hair shedding, short-duration botulinum like TrenibotE for expression and glabellar lines. A staged options menu for first-time users.

The integrated message of four posters

Two industry messages emerge.

First, the botulinum toxin category subdivides by time profile. From a single standard (Type A, 3-4 months) to a matrix forming around TrenibotE (2-3 weeks) and potential other options. Users can choose by event timing and procedure experience.

Second, GLP-1 patients form a new procedure market. The 32% first-timer share is a significant variable for procedure market growth in the next 12-24 months. Procedural decision units shift from a single prescription to a staged matrix.

For consumers, the change is clear. From “Botox = one option” to a matrix subdivided by time profile and procedure experience. TrenibotE Korean availability requires separate steps after US FDA approval, with possibility around 2027-2028.